WallStreetZenWallStreetZen

NASDAQ: VCEL
Vericel Corp Stock

$52.33+2.77 (+5.59%)
Updated Mar 27, 2024
VCEL Price
$52.33
Fair Value Price
$53.23
Market Cap
$2.53B
52 Week Low
$28.02
52 Week High
$52.43
P/E
-747.57x
P/B
11.18x
P/S
8.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$197.52M
Earnings
-$3.18M
Gross Margin
68.6%
Operating Margin
-0.9%
Profit Margin
-1.6%
Debt to Equity
0.57
Operating Cash Flow
$35M
Beta
1.39
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A

VCEL Overview

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VCEL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VCEL ($52.33) is undervalued by 1.7% relative to our estimate of its Fair Value price of $53.23 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VCEL ($52.33) is not significantly undervalued (1.7%) relative to our estimate of its Fair Value price of $53.23 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VCEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VCEL due diligence checks available for Premium users.

Be the first to know about important VCEL news, forecast changes, insider trades & much more!

VCEL News

Valuation

VCEL fair value

Fair Value of VCEL stock based on Discounted Cash Flow (DCF)
Price
$52.33
Fair Value
$53.23
Undervalued by
1.70%
VCEL ($52.33) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VCEL ($52.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VCEL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VCEL price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-747.57x
Industry
14.3x
Market
44.45x

VCEL price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
11.18x
Industry
6.2x
VCEL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VCEL's financial health

Profit margin

Revenue
$65.0M
Net Income
$13.0M
Profit Margin
20%
VCEL's Earnings (EBIT) of -$1.77M... subscribe to Premium to read more.
Interest Coverage Financials
VCEL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$353.7M
Liabilities
$127.7M
Debt to equity
0.57
VCEL's short-term assets ($205.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCEL's short-term assets ($205.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCEL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VCEL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$10.1M
Investing
-$8.1M
Financing
$1.3M
VCEL's operating cash flow ($35.31M)... subscribe to Premium to read more.
Debt Coverage Financials

VCEL vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VCEL$2.53B+5.59%-747.57x11.18x
ALPN$2.53B+3.20%-60.39x7.73x
RYTM$2.51B+5.72%-13.06x14.80x
RCKT$2.47B+2.60%-9.33x5.01x
MRUS$2.59B-0.36%-14.92x7.27x

Vericel Stock FAQ

What is Vericel's quote symbol?

(NASDAQ: VCEL) Vericel trades on the NASDAQ under the ticker symbol VCEL. Vericel stock quotes can also be displayed as NASDAQ: VCEL.

If you're new to stock investing, here's how to buy Vericel stock.

What is the 52 week high and low for Vericel (NASDAQ: VCEL)?

(NASDAQ: VCEL) Vericel's 52-week high was $52.43, and its 52-week low was $28.02. It is currently -0.19% from its 52-week high and 86.76% from its 52-week low.

How much is Vericel stock worth today?

(NASDAQ: VCEL) Vericel currently has 48,290,164 outstanding shares. With Vericel stock trading at $52.33 per share, the total value of Vericel stock (market capitalization) is $2.53B.

Vericel stock was originally listed at a price of $700.00 in Dec 31, 1997. If you had invested in Vericel stock at $700.00, your return over the last 26 years would have been -92.52%, for an annualized return of -9.49% (not including any dividends or dividend reinvestments).

How much is Vericel's stock price per share?

(NASDAQ: VCEL) Vericel stock price per share is $52.33 today (as of Mar 27, 2024).

What is Vericel's Market Cap?

(NASDAQ: VCEL) Vericel's market cap is $2.53B, as of Mar 28, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vericel's market cap is calculated by multiplying VCEL's current stock price of $52.33 by VCEL's total outstanding shares of 48,290,164.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.